Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does EVOLOCUMAB Cause Deep vein thrombosis? 44 Reports in FDA Database

Lower Your Cholesterol — The Natural Way

The Oxidized Cholesterol Strategy: a science-backed plan for heart health.

See the Strategy

According to the FDA Adverse Event Reporting System (FAERS), 44 reports of Deep vein thrombosis have been filed in association with EVOLOCUMAB (REPATHA). This represents 0.0% of all adverse event reports for EVOLOCUMAB.

44
Reports of Deep vein thrombosis with EVOLOCUMAB
0.0%
of all EVOLOCUMAB reports
1
Deaths
20
Hospitalizations

How Dangerous Is Deep vein thrombosis From EVOLOCUMAB?

Of the 44 reports, 1 (2.3%) resulted in death, 20 (45.5%) required hospitalization, and 2 (4.5%) were considered life-threatening.

Is Deep vein thrombosis Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for EVOLOCUMAB. However, 44 reports have been filed with the FAERS database.

What Other Side Effects Does EVOLOCUMAB Cause?

Device difficult to use (31,807) Drug dose omission by device (23,957) Wrong technique in product usage process (21,664) Accidental exposure to product (16,160) Injection site pain (9,988) Product storage error (6,606) Back pain (5,254) Myalgia (5,061) Drug dose omission (4,914) Injection site bruising (4,409)

What Other Drugs Cause Deep vein thrombosis?

LENALIDOMIDE (3,286) RIVAROXABAN (3,180) TESTOSTERONE (2,213) APIXABAN (1,944) ETHINYL ESTRADIOL\ETONOGESTREL (1,577) RITUXIMAB (1,287) METHOTREXATE (1,146) DROSPIRENONE\ETHINYL ESTRADIOL (1,139) DEXAMETHASONE (1,067) ADALIMUMAB (1,056)

Which EVOLOCUMAB Alternatives Have Lower Deep vein thrombosis Risk?

EVOLOCUMAB vs EXELON EVOLOCUMAB vs EXEMESTANE EVOLOCUMAB vs EXENATIDE EVOLOCUMAB vs EXFORGE EVOLOCUMAB vs EXJADE

Related Pages

EVOLOCUMAB Full Profile All Deep vein thrombosis Reports All Drugs Causing Deep vein thrombosis EVOLOCUMAB Demographics